-+ 0.00%
-+ 0.00%
-+ 0.00%

Lundbeck Secures US FDA Fast Track Designation for Narcolepsy Drug

MT Newswires·07/23/2026 04:14:55
Listen to the news
04:14 AM EDT, 07/23/2026 (MT Newswires) -- H. Lundbeck (HLUN-A.CO, HLUN-B.CO) said Thursday it received the US Food and Drug Administration's fast-track designation for its Lu AH69593 investigational drug for the treatment of narcolepsy. The Danish biopharmaceutical company said the small-molecule orexin 2 receptor agonist, which is currently in phase 1b development, is one of several investigational compounds in its portfolio for sleep-wake disorders.